Now Available: The Gvoke HypoPen^TM!

    

People with diabetes and their caregivers often struggle with the management of their condition, especially managing their “lows”. It can be a difficult subject for Diabetes Care and Education Specialists to discuss with their patients because every person may experience it differently. As experts, you know that hypoglycemia can quickly evolve from a mild event to an emergency, so prompt and reliable intervention is critically important for people with Type 1 or Type 2 diabetes on insulin. However, many people still either have no glucagon option on-hand in case of emergency, or have an old school emergency kit that requires a complex series of preparation and administration steps that studies have shown only ~30% of people can actually use correctly¹. 

We have a chance to change this paradigm! Xeris Pharmaceuticals is thrilled to announce the next generation of Gvoke^TM is now available - Gvoke HypoPen^TM (glucagon injection)! Gvoke HypoPen is the first auto-injector for treatment of severe hypoglycemia in adults and children with diabetes ages 2 and above².

Gvoke HypoPen offers simple administration, with the certainty of delivery. It is:

• Easy to Use: premixed and ready-to-go²
• Reliable Method of Delivery: 99% of people were able to use it correctly, in a study³
• Proven to Work: 99% of adults and 100% of kids had their blood sugars raised to safe levels²

Anyone can use Gvoke HypoPen in just 2 simple steps.

Gvoke HypoPen comes in two doses (1mg for adults and 0.5mg for children) and is available as a 2-pack. This means your patients can get two devices for one copay.  For a limited time, a $0 copay card will be available for commercially eligible patients*. To download a copay card, please visit https://www.gvokeglucagon.com/savings-and-support.

To Request a Demo Device

• Please visit https://www.gvokeglucagon.com/hcp to request a Gvoke HypoPen^TM demo device and to find helpful videos and resources you can use with your patients during telehealth visits.

  To Learn More

• If you would like to attend a virtual webinar on Gvoke HypoPen, please sign up here.
• To connect with your local sales representative, please click here.
• Any other questions, please contact the Xeris Contact Center at 1-877-XERIS-37.

The simplicity of Gvoke HypoPen allows all of us to evolve the paradigm in managing severe hypoglycemia. Xeris Pharmaceuticals is excited to continue partnering with ADCES on this endeavor.

INDICATION AND IMPORTANT SAFETY INFORMATION

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications
GVOKE is contraindicated in patients with pheochromocytoma, insulinoma, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions
GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.
Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.

GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.

Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas has been reported postmarketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia.

Adverse Reactions
Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.

Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE^TM may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.

Click here to see Full Prescribing Information for Gvoke.

​

1. Virginia Valentine, Brett Newswanger, Steve Prestrelski, Anthony D. Andre, and Mark Garibaldi. (2019). Human Factors Usability and Validation Studies of a Glucagon Autoinjector in a Simulated Severe Hypoglycemia Rescue Situation, Diabetes Technology & Therapeutics. Vol. 21, No.9, https://doi.org/10.1089/dia.2019.01482.
2. Gvoke Prescribing Information, 09/2019.
3. Newswanger B, Prestrelski S, Andre AD. Human factors studies of a prefilled syringe with stable liquid glucagon in a simulated severe hypoglycemia rescue situation. Expert Opin Drug Deliv. 2019;16(9):1015-1025.

Gvoke™, Gvoke HypoPen^TM, Xeris Pharmaceuticals®, and their associated logos are trademarks of Xeris Pharmaceuticals, Inc. All other trademarks referenced herein are the property of their respective owners.

Copyright ©2020 Xeris Pharmaceuticals, Inc. All rights reserved.  US-GVKHP-20-00044  05/2020